| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9339504 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jul, 2028
(4 years from now) | |
| US8840925 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jul, 2028
(4 years from now) | |
| US7919115 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jan, 2029
(4 years from now) | |
Lamictal Odt is owned by Glaxosmithkline Llc.
Lamictal Odt contains Lamotrigine.
Lamictal Odt has a total of 3 drug patents out of which 0 drug patents have expired.
Lamictal Odt was authorised for market use on 08 May, 2009.
Lamictal Odt is available in tablet, orally disintegrating;oral dosage forms.
Lamictal Odt can be used as lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures.
The generics of Lamictal Odt are possible to be released after 04 January, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | May 18, 2018 |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 08 May, 2009
Treatment: Lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
LAMICTAL ODT family patents
